Shots:
- Boston Scientific to acquire Preventice for ~$1.2B including $925M as up front, up to an additional $300M as commercial milestones. However, Boston Scientific has built up a 22% stake in Preventice, which is expected to lower up front to $720M upfront & $230 million in milestone respectively
- The acquisition is expected to be close in mid-2021. The acquisition will add external cardiac monitoring technologies and services provider to Boston Scientific and expand its rhythm management diagnostics portfolio and capabilities
- The Preventice portfolio includes the BodyGuardian family of remote, wearable cardiac monitors for adult and pediatric patients
Click here to read full press release/ article | Ref: Boston Scientific| Image: CRG
The post Boston Scientific to Acquire Preventice for ~$1.2B first appeared on PharmaShots.
